- Home
- PROK vs MTLS Comparison
PROK vs MTLS Comparison
Compare PROK & MTLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PROK | MTLS |
|---|---|---|
| Founded | 2015 | 1990 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 359.4M | 395.1M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PROK | MTLS |
|---|---|---|
| Price | $1.13 | $7.02 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 3 |
| Target Price | $6.50 | ★ $9.95 |
| AVG Volume (30 Days) | ★ 1.4M | 220.0K |
| Earning Date | 11-24-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $893,000.00 | N/A |
| Revenue This Year | N/A | $3.97 |
| Revenue Next Year | N/A | $5.95 |
| P/E Ratio | ★ N/A | $61.39 |
| Revenue Growth | ★ 1075.00 | N/A |
| 52 Week Low | $0.87 | $4.78 |
| 52 Week High | $2.66 | $8.82 |
Technical Indicators
Market Signals| Indicator | PROK | MTLS |
|---|---|---|
| Relative Strength Index (RSI) | 35.75 | 39.80 |
| Support Level | $0.87 | $6.37 |
| Resistance Level | $2.01 | $7.50 |
| Average True Range (ATR) | 0.15 | 0.38 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 34.46 | 27.37 |
Price Performance
Historical ComparisonAbout PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About MTLS Materialise NV
Materialise NV is a provider of 3D-printed medical devices and software and a pioneer in additive manufacturing software and services. The company operates through three principal segments: Materialise Software, Materialise Medical, and Materialise Manufacturing, with the Materialise Medical segment generating maximum revenue. The Materialise Medical segment develops and delivers medical software solutions, medical devices, and related products and services; the Materialise Software segment develops and delivers additive manufacturing software solutions and related services; and the Materialise Manufacturing segment delivers 3D-printed products and related services. The company generates maximum revenue from the United States of America.